Patient Search
KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story |
If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story. https://momentum.vicc.org/2022/04/brighter-outlook/ |
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Miscellaneous
Miscellaneous
This is an observational case-control study to train and validate a genome-wide methylome
enrichment platform to detect multiple cancer types and to differentiate amongst cancer
types. The cancers included in this study are brain, breast, bladder, cervical, colorectal,
endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma,
multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers
were selected based on their prevalence and mortality to maximize impact on clinical care.
Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal
residual disease after completion of cancer treatment and to detect relapse prior to clinical
presentation will be evaluated in four cancer types (breast, colorectal, lung, prostate).
These cancers were selected based on the existing clinical landscape and treatment
availability.
enrichment platform to detect multiple cancer types and to differentiate amongst cancer
types. The cancers included in this study are brain, breast, bladder, cervical, colorectal,
endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma,
multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers
were selected based on their prevalence and mortality to maximize impact on clinical care.
Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal
residual disease after completion of cancer treatment and to detect relapse prior to clinical
presentation will be evaluated in four cancer types (breast, colorectal, lung, prostate).
These cancers were selected based on the existing clinical landscape and treatment
availability.
Miscellaneous
N/A
Rini, Brian
NCT05366881
VICCMD21111
Educational Telehealth Program for the Delivery of Care to Cancer Patients in Rural Communities, ENCORE Study
Miscellaneous
Miscellaneous
This clinical trial evaluates the clinical effectiveness of a multi-level telehealth-based intervention for cancer patients in rural communities. Rural residents face limited accessibility to cancer treatment and supportive care services, transportation barriers, and financial issues. Cancer Thriving and Surviving is an evidence-based self-management intervention with demonstrated efficacy across numerous chronic health conditions with dissemination across the US, inclusive of rural communities. This trial evaluates whether the evidence-based Cancer Thriving and Surviving intervention delivered through telehealth among rural patients may improve patient outcomes.
Miscellaneous
N/A
Friedman, Debra
NCT04758338
VICCPED2013
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Multiple Cancer Types
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Lymphoma,
Miscellaneous,
Pediatric Solid Tumors
N/A
Borinstein, Scott
NCT03155620
COGAPEC1621SC
Improving Care after Inherited Cancer Testing (IMPACT) Study
Miscellaneous
Miscellaneous
This clinical trial investigates factors associated with access to genetic risk assessment, counseling, and testings services. The trial also seeks to refine and evaluate the effectiveness of online tools on improving cancer risk management practices and family communication of genetic test results.
Miscellaneous
N/A
Pal, Tuya
NCT04763915
VICCSUPP2112
Inherited CAncer REgistry (ICARE) Initiative
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Pal, Tuya
NCT03231891
VICCMD1712
REACH (Research, Education, Advocacy, Clinical Care and Health) for Survivorship Program: Long Term Effects for Survivors of Cancer
Multiple Cancer Types
Miscellaneous,
Pediatrics
N/A
Esbenshade, Adam
VICCPED0710
Infectious Disease Outcomes in Pediatric Oncology Patients
Multiple Cancer Types
Miscellaneous,
Pediatrics
N/A
Esbenshade, Adam
VICCPED14127
Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Kitko, Carrie
VICCPED1544
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Friedman, Debra
COGAPEC14B1